In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

or advanced systemic therapy for prostate cancer. Data analysis included 182 patients who had a median pre-scan PSA level of 2.6 ng/mL Overall, 84% of the patients had positive PSMA-PET/CT results ...

WVU Medicine St. Joseph’s Hospital is proud to announce the addition of two cutting-edge imaging services: PET/CT and ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) detected metastatic disease in 46% of patients with high-risk prostate cancer previously classified as nonmetastatic by ...

that binds to prostate cancer cells, making them visible on PET scans. Unlike conventional imaging, which provides only anatomical details, PSMA-PET offers functional imaging that reveals the cancer’s ...

PSMA-PET leverages ‘radiotracers’ that bind to prostate cancer cells, making them visible on PET scans and providing functional imaging that reveals the biological activity of cancer.

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...

PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and enabling timely interventions.

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate cancer detection, while the DOTA PET CT scan aids in identifying ...